SentinelOne Partners With SecBI To Provide Threat Visibility, Containment and Remediation
SentinelOne has partnered with SecBI, a provider of automated cyber threat detection and investigation. By combining SentinelOne’s next-gen threat visibility, containment and remediation capabilities with SecBI’s Autonomous Investigation technology, security professionals will be able to shed light into every single behavior in an organization’s network, placing the spotlight on and enabling actionable defense against all incidents that happen and/or involve activities on the endpoint and in the network, the company described.
“In today’s world, it is not a matter of if you will be the target of a cyber-attack, it’s a matter of when,” said Tomer Weingarten, CEO and co-founder, SentinelOne. “By combining SecBI’s automated threat detection and network analytics with SentinelOne’s autonomous endpoint protection, organizations can overcome today’s most prominent cyber threats through complete visibility and action — beyond endpoints to complete network visibility.”
With SentinelOne’s bidirectional APIs, SecBI customers gain rich visibility into events, files and processes at the endpoint. Coupled with the ability to power threat detection with static and behavioral artificial intelligence, organizations can automate the response workflow and help achieve real-time security with speed and simplicity. Organizations benefit from SecBI’s full scope incident reporting that identifies all affected devices and users into the one relevant incident, presented in such a comprehensive, unified manner for immediate and complete remediation.
“At SecBI, our focus is on solving security operations’ primary challenge by unveiling the full scope of an incident in minutes, for faster and accurate mitigation,” said Gilad Peled, CEO, SecBI. “Working with SentinelOne will add critical endpoint protection for enhanced visibility throughout the entire threat lifecycle. Our customers benefit from next-gen network analytics without any appliance installation.”
Visit www.sentinelone.com for more information.